By Matteo Castia

Oxford BioMedica PLC said Friday that French pharma group Sanofi SA intends to terminate its collaboration and license agreement with Oxford BioMedica in the field of hemophilia gene therapy.

The gene and cell-therapy group said it expects a negligible impact on revenue in the next 24 months due to the termination.

Write to Matteo Castia at matteo.castia@dowjones.com

(END) Dow Jones Newswires

March 19, 2021 04:08 ET (08:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.